DGS Capital Management LLC Makes New $182,000 Investment in InMode Ltd. (NASDAQ:INMD)

DGS Capital Management LLC purchased a new stake in InMode Ltd. (NASDAQ:INMD) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 10,756 shares of the healthcare company’s stock, valued at approximately $182,000.

A number of other hedge funds also recently made changes to their positions in INMD. National Bank of Canada FI grew its holdings in InMode by 6.2% in the 3rd quarter. National Bank of Canada FI now owns 9,985 shares of the healthcare company’s stock worth $169,000 after buying an additional 579 shares in the last quarter. Carmel Capital Partners LLC grew its stake in shares of InMode by 6.9% in the third quarter. Carmel Capital Partners LLC now owns 11,511 shares of the healthcare company’s stock worth $195,000 after purchasing an additional 741 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of InMode by 4.6% during the third quarter. Franklin Resources Inc. now owns 17,559 shares of the healthcare company’s stock valued at $292,000 after purchasing an additional 768 shares during the period. Meritage Portfolio Management increased its holdings in shares of InMode by 9.5% during the third quarter. Meritage Portfolio Management now owns 14,765 shares of the healthcare company’s stock valued at $250,000 after purchasing an additional 1,284 shares during the period. Finally, Inspire Advisors LLC raised its stake in shares of InMode by 9.0% during the second quarter. Inspire Advisors LLC now owns 21,433 shares of the healthcare company’s stock valued at $391,000 after purchasing an additional 1,778 shares in the last quarter. Institutional investors own 68.04% of the company’s stock.

Wall Street Analyst Weigh In

INMD has been the subject of a number of recent analyst reports. Barclays decreased their target price on shares of InMode from $29.00 to $27.00 and set an “overweight” rating for the company in a research report on Monday, October 14th. Needham & Company LLC reiterated a “hold” rating on shares of InMode in a report on Thursday, October 31st. Finally, BTIG Research assumed coverage on InMode in a report on Thursday, October 17th. They set a “buy” rating and a $25.00 target price on the stock. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, InMode has a consensus rating of “Hold” and an average target price of $22.60.

InMode Trading Down 1.3 %

NASDAQ:INMD opened at $18.26 on Friday. The company has a 50-day moving average of $18.08 and a 200-day moving average of $17.50. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of 9.87 and a beta of 2.07. InMode Ltd. has a twelve month low of $14.87 and a twelve month high of $26.80.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.